Delving into the Latest Updates on SB-649701 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

SB-649701

Target

CCR8

Action

inhibitors

Mechanism

CCR8 inhibitor(C-C motif chemokine receptor 8 inhibitors)

Therapeutic Areas-

Active Indication-

Inactive Indication-

Originator Organization

GSK Plc

Active Organization-

Inactive Organization

GSK Plc

License Organization-

Drug Highest PhasePendingPreclinical

First Approval Date-

Regulation-

Author: Wang, Feng ; Lindon, Matthew J. ; Nguyen, Cuc ; Foley, James J. ; Harker, Andy J. ; Rivero, Ralph A. ; Belmonte, Kristen E. ; Wang, Yonghui ; Browning, Chris ; Hartmann, Guido ; Hancock, Ashley P. ; Fornwald, James A. ; Vinader, Victoria M. ; Morrow, Dwight M. ; Kerns, Jeffery K. ; Connor, Helen E. ; Barrett, Victoria J. ; Moore, Michael L. ; Andrew, David P. ; Jin, Jian ; Rao, Parvathi ; Sarau, Henry M. ; Jurewicz, Anthony J. ; Stevenson, Graeme I.

High-throughput screening of the corporate compound collection led to the discovery of a novel series of N-substituted-5-aryl-oxazolidinones as potent human CCR8 antagonists. The synthesis, structure-activity relationships, and optimization of the series that led to the identification of SB-649701 (1a), are described.

100 Deals associated with SB-649701

Login to view more data